Log In
Print this Print this

Belsomra, suvorexant (MK-4305)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionDual orexin receptor antagonist
Molecular Target Orexin 1 receptor (OX1R) (HCRTR1) ; Orexin 2 receptor (OX2R) (HCRTR2)
Mechanism of ActionOrexin receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInsomnia
Indication DetailsTreat insomnia
Regulatory Designation U.S. - Undisclosed Review (Treat insomnia)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today